,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter, June 30, 2019, was approximately $241 billion. This excludes shares of common stock held by directors and executive officers at June 30, 2019. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non voting common stock.",241,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,pfe,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2019, was approximately $241 billion.",approximately $241 billion,MONEY,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2019, was approximately $241 billion.","['aggregate market value of voting stock', 'non affiliates', 'reference to closing price', 'last business day of registrant', 'aggregate market value', 'voting stock', 'non affiliates', 'closing price']","['voting stock', 0.33261311054229736, 'What is approximately $241 billion ?', 'voting stock']",voting stock,0.3326131105422973,What is approximately $241 billion ?,voting stock,the aggregate market value of the registrant's voting stock held by non affiliates
1,"The number of shares outstanding of the registrant's common stock as of February 25, 2020 was 5,547,639,005 shares of common stock, all of one class.","5,547,639,005","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,pfe,"The number of shares outstanding of the registrant’s common stock as of February 25, 2020 was 5,547,639,005 shares of common stock, all of one class.","5,547,639,005",CARDINAL,"The number of shares outstanding of the registrant’s common stock as of February 25, 2020 was 5,547,639,005 shares of common stock, all of one class.","['number of outstanding shares', 'number', 'shares of common stock', 'outstanding shares', 'registrant common stock', 'common stock']","['outstanding shares', 0.959707498550415, 'how many outstanding shares ?', '5,547,639,005']",outstanding shares,0.959707498550415,how many outstanding shares ?,"5,547,639,005",Shares outstanding of registrant's common stock
2,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter, July 4, 2021, was approximately $223 billion. This excludes shares of common stock held by directors and executive officers at July 4, 2021. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non voting common stock.",223,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,pfe,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, July 4, 2021, was approximately $223 billion.",approximately $223 billion,MONEY,"The aggregate market value of the voting stock held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, July 4, 2021, was approximately $223 billion.","['aggregate market value of voting stock', 'non affiliates', 'reference to closing price', 'last business day of registrant', 'aggregate market value', 'voting stock', 'non affiliates', 'closing price']","['voting stock', 0.2682467997074127, 'What is approximately $223 billion ?', 'voting stock']",voting stock,0.2682467997074127,What is approximately $223 billion ?,voting stock,aggregate market value of voting stock held by non affiliates
3,"The number of shares outstanding of the registrant's common stock as of February 22, 2022 was 5,623,346,471 shares of common stock, all of one class.","5,623,346,471","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,pfe,"The number of shares outstanding of the registrant’s common stock as of February 22, 2022 was 5,623,346,471 shares of common stock, all of one class.","5,623,346,471",CARDINAL,"The number of shares outstanding of the registrant’s common stock as of February 22, 2022 was 5,623,346,471 shares of common stock, all of one class.","['number of outstanding shares', 'number', 'shares of common stock', 'outstanding shares', 'registrant common stock', 'common stock']","['registrant common stock', 0.9478886723518372, 'how many registrant common stock ?', '5,623,346,471']",registrant common stock,0.9478886723518372,how many registrant common stock ?,"5,623,346,471",Shares of common stock outstanding
4,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020",27,"['Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,pfe,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020",27,CARDINAL,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020","['Preferred stock at stated value', 'stated value']","['shares authorized', 0.9733154773712158, 'What is 27 ?', 'shares authorized']",shares authorized,0.9733154773712158,What is 27 ?,shares authorized,Preferred stock
5,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020",27,"['Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,pfe,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020",27,CARDINAL,"Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020","['Preferred stock at stated value', 'stated value']","['shares authorized', 0.9733154773712158, 'What is 27 ?', 'shares authorized']",shares authorized,0.9733154773712158,What is 27 ?,shares authorized,Preferred stock at stated value
6,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","12,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,pfe,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","12,000",CARDINAL,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407",[],"['shares authorized', 0.933739423751831, 'What is 12,000 ?', 'shares authorized']",shares authorized,0.933739423751831,"What is 12,000 ?",shares authorized,Shares authorized
7,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","12,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,pfe,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","12,000",CARDINAL,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407",[],"['shares authorized', 0.933739423751831, 'What is 12,000 ?', 'shares authorized']",shares authorized,0.933739423751831,"What is 12,000 ?",shares authorized,shares authorized
8,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","9,471","['Common stock, shares, issued']",us-gaap_CommonStockSharesIssued,sharesItemType,pfe,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","2021—9,471",CARDINAL,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407",[],"['issued', 0.8763958215713501, 'What is 2021—9,471 ?', 'issued']",issued,0.8763958215713501,"What is 2021—9,471 ?",issued,Common stock shares authorized
9,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","9,407","['Common stock, shares, issued']",us-gaap_CommonStockSharesIssued,sharesItemType,pfe,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407","2020—9,407",CARDINAL,"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021—9,471; 2020—9,407",[],"['Common stock', 0.3227942883968353, 'What is 2020—9,407 ?', 'Common stock']",Common stock,0.3227942883968353,"What is 2020—9,407 ?",Common stock,Common stock par value
10,32% equity method investment in the Consumer Healthcare JV received in exchange for contributing Pfizer's Consumer Healthcare business(a),32,"['Equity method investment, ownership percentage']",us-gaap_EquityMethodInvestmentOwnershipPercentage,percentItemType,pfe,32% equity method investment in the Consumer Healthcare JV received in exchange for contributing Pfizer’s Consumer Healthcare business(a),32%,PERCENT,32% equity method investment in the Consumer Healthcare JV received in exchange for contributing Pfizer’s Consumer Healthcare business,"['% method investment in Consumer Healthcare JV', 'exchange', '% method investment', 'Healthcare business']","['equity', 0.49392545223236084, 'What is 32% ?', 'equity']",equity,0.4939254522323608,What is 32% ?,equity,Equity method investment
11,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.",8.3,"['Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed']",pfe_DeconsolidationGainLossAmountNetOfCashConveyed,monetaryItemType,pfe,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.",$8.3 billion,MONEY,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.","['Gain on completion', 'completion of JV transaction', 'net of cash', 'receipt of % method investment', '% method investment in new company', 'exchange for net assets', 'net of cash', 'JV transaction', '% method investment', 'new company', 'net assets', 'operating activities', 'Other investing activities']","['completion of JV transaction', 0.5604379773139954, 'what is completion of JV transaction ?', '$8.3 billion Gain']",completion of JV transaction,0.5604379773139954,what is completion of JV transaction ?,$8.3 billion Gain,Gain on completion of Consumer Healthcare JV transaction
12,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.",32,"['Equity method investment, ownership percentage']",us-gaap_EquityMethodInvestmentOwnershipPercentage,percentItemType,pfe,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.",32%,PERCENT,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.","['Gain on completion', 'completion of JV transaction', 'net of cash', 'receipt of % method investment', '% method investment in new company', 'exchange for net assets', 'net of cash', 'JV transaction', '% method investment', 'new company', 'net assets', 'operating activities', 'Other investing activities']","['% method investment', 0.48335859179496765, 'what is % method investment ?', '32% equity']",% method investment,0.4833585917949676,what is % method investment ?,32% equity,equity method investment
13,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.",15.7,['Equity method investments'],us-gaap_EquityMethodInvestmentsFairValueDisclosure,monetaryItemType,pfe,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.",$15.7 billion,MONEY,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.","['Gain on completion', 'completion of JV transaction', 'net of cash', 'receipt of % method investment', '% method investment in new company', 'exchange for net assets', 'net of cash', 'JV transaction', '% method investment', 'new company', 'net assets', 'operating activities', 'Other investing activities']","['receipt of % method investment', 0.15960268676280975, 'what is receipt of % method investment ?', '$15.7 billion']",receipt of % method investment,0.1596026867628097,what is receipt of % method investment ?,$15.7 billion,Equity method investment
14,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.",7.6,['Deconsolidation net assets contributed'],pfe_DeconsolidationNetAssetsContributed,monetaryItemType,pfe,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.",$7.6 billion,MONEY,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.","['Gain on completion', 'completion of JV transaction', 'net of cash', 'receipt of % method investment', '% method investment in new company', 'exchange for net assets', 'net of cash', 'JV transaction', '% method investment', 'new company', 'net assets', 'operating activities', 'Other investing activities']","['net assets', 0.718233048915863, 'what is net assets ?', '$7.6 billion']",net assets,0.718233048915863,what is net assets ?,$7.6 billion,Receipt of equity method investment
15,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.",146,"['Deconsolidation, cash conveyed']",pfe_DeconsolidationGainLossAmountCashConveyed,monetaryItemType,pfe,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.",$146 million,MONEY,"The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net.","['Gain on completion', 'completion of JV transaction', 'net of cash', 'receipt of % method investment', '% method investment in new company', 'exchange for net assets', 'net of cash', 'JV transaction', '% method investment', 'new company', 'net assets', 'operating activities', 'Other investing activities']","['net of cash', 0.8081851601600647, 'what is net of cash ?', '$146 million']",net of cash,0.8081851601600647,what is net of cash ?,$146 million,"""Gain on completion of Consumer Healthcare JV transaction"""
16,"At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. See Note 17. On December 31, 2021, we completed the sale of our Meridian subsidiary, the manufacturer of EpiPen and other auto injector products. Prior to its sale, Meridian was managed within the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. On December 21, 2020, Pfizer and Viatris completed the termination of a pre existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (the Mylan Japan collaboration) pursuant to an agreement dated November 13, 2020, and we transferred related inventories and operations that were part of the Mylan Japan collaboration to Viatris. On November 16, 2020, we completed the spin off and the combination of our Upjohn Business with Mylan to form Viatris. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan Japan collaboration were reflected as discontinued operations for all periods presented. The assets and liabilities associated with Meridian and the Mylan Japan collaboration are classified as assets and liabilities of discontinued operations as of December 31, 2020. Upon completion of the spin off of the Upjohn Business on November 16, 2020, the Upjohn assets and liabilities were derecognized from our consolidated balance sheet and are reflected in Retained Earnings–Distribution of Upjohn Business in the consolidated statement of equity. Prior to the spin off of the Upjohn Business in November 2020, the Upjohn Business, the Mylan Japan collaboration and Meridian were managed as part of our former Upjohn operating segment. With the separation of the Upjohn Business, the Mylan Japan collaboration and Meridian, as well as the formation of the Consumer Healthcare JV in 2019, Pfizer transformed into a more focused, global leader in science based innovative medicines and vaccines. Certain prior year amounts have been reclassified to conform with the current year presentation. In addition, other acquisitions and business development activities completed in 2021, 2020 and 2019 impacted financial results in the periods presented. See Note 2.",two,['Number of operating segments'],us-gaap_NumberOfOperatingSegments,integerItemType,pfe,"At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.",two,CARDINAL,"At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.","['beginning of fiscal fourth quarter', 'fiscal fourth quarter', 'leading supplier of active pharmaceutical ingredients', 'fiscal fourth quarter', 'commercial operations', 'commercial operations', 'new global structure', 'single manager', 'active pharmaceutical ingredients']","['fiscal fourth quarter', 0.8599969148635864, 'how many fiscal fourth quarter ?', 'two']",fiscal fourth quarter,0.8599969148635864,how many fiscal fourth quarter ?,two,operating segments
17,"In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting). Under the prior policy, we deferred recognition of these gains and losses in Accumulated other comprehensive loss. The accumulated actuarial gains/losses outside of a ""corridor"" were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net.",6.0,"['Accumulated other comprehensive loss', 'Increase to AOCI']",us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax,monetaryItemType,pfe,"This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss.",$6.0 billion,MONEY,"This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss.","['retrospective basis for prior periods', 'effect decrease to Retained earnings', 'Retained earnings', 'effect decrease with corresponding offset', 'corresponding offset to Accumulated other comprehensive loss', 'retrospective basis', 'prior periods', 'effect decrease', 'corresponding offset', 'Accumulated other comprehensive loss']","['Retained earnings', 0.9791467189788818, 'what is Retained earnings ?', '$6.0 billion']",Retained earnings,0.9791467189788818,what is Retained earnings ?,$6.0 billion,Retained earnings
18,"In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting). Under the prior policy, we deferred recognition of these gains and losses in Accumulated other comprehensive loss. The accumulated actuarial gains/losses outside of a ""corridor"" were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net.",6.0,['Retained earnings'],us-gaap_RetainedEarningsAccumulatedDeficit,monetaryItemType,pfe,"This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss.",$6.0 billion,MONEY,"This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to Retained earnings of $6.0 billion, with a corresponding offset to Accumulated other comprehensive loss.","['retrospective basis for prior periods', 'effect decrease to Retained earnings', 'Retained earnings', 'effect decrease with corresponding offset', 'corresponding offset to Accumulated other comprehensive loss', 'retrospective basis', 'prior periods', 'effect decrease', 'corresponding offset', 'Accumulated other comprehensive loss']","['Retained earnings', 0.9791467189788818, 'what is Retained earnings ?', '$6.0 billion']",Retained earnings,0.9791467189788818,what is Retained earnings ?,$6.0 billion,Cumulative effect decrease
19,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",1,"['Concentration risk, amount']",pfe_ConcentrationRiskAmount,monetaryItemType,pfe,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.",more than $1 billion,MONEY,"We recorded direct product sales andor Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.","['andor Alliance revenues', 'andor Alliance revenues']","['andor Alliance revenues', 0.5016672611236572, 'what is andor Alliance revenues ?', 'more than $1 billion']",andor Alliance revenues,0.5016672611236572,what is andor Alliance revenues ?,more than $1 billion,direct product sales and/or Alliance revenues
20,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",1,"['Concentration risk, amount']",pfe_ConcentrationRiskAmount,monetaryItemType,pfe,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.",more than $1 billion,MONEY,"We recorded direct product sales andor Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.","['andor Alliance revenues', 'andor Alliance revenues']","['andor Alliance revenues', 0.5016672611236572, 'what is andor Alliance revenues ?', 'more than $1 billion']",andor Alliance revenues,0.5016672611236572,what is andor Alliance revenues ?,more than $1 billion,direct product sales and/or Alliance revenues
21,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",1,"['Concentration risk, amount']",pfe_ConcentrationRiskAmount,monetaryItemType,pfe,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.",more than $1 billion,MONEY,"We recorded direct product sales andor Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019.","['andor Alliance revenues', 'andor Alliance revenues']","['andor Alliance revenues', 0.5016672611236572, 'what is andor Alliance revenues ?', 'more than $1 billion']",andor Alliance revenues,0.5016672611236572,what is andor Alliance revenues ?,more than $1 billion,direct product sales andor Alliance revenues
22,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",75,"['Percentage of total revenues', 'Concentration risk, percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,pfe,"In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.",75%,PERCENT,"In the aggregate, these direct products sales andor alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.","['% of revenues', '% of revenues', '% of revenues', 'products andor product revenues']","['products andor product revenues', 0.7761396765708923, 'what is products andor product revenues ?', '75%']",products andor product revenues,0.7761396765708923,what is products andor product revenues ?,75%,Direct product sales andor alliance product revenues
23,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",54,"['Percentage of total revenues', 'Concentration risk, percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,pfe,"In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.",54%,PERCENT,"In the aggregate, these direct products sales andor alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.","['% of revenues', '% of revenues', '% of revenues', 'products andor product revenues']","['revenues', 0.3957328200340271, 'What is 54% ?', 'revenues']",revenues,0.3957328200340271,What is 54% ?,revenues,Revenues in 2020
24,"We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019. See Note 17B for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.",49,"['Percentage of total revenues', 'Concentration risk, percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,pfe,"In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.",49%,PERCENT,"In the aggregate, these direct products sales andor alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49% of our revenues in 2019.","['% of revenues', '% of revenues', '% of revenues', 'products andor product revenues']","['revenues', 0.40942367911338806, 'What is 49% ?', 'revenues']",revenues,0.409423679113388,What is 49% ?,revenues,Alliance product revenues
25,"Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.",2.0,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,pfe,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",approximately $2.0 billion,MONEY,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",['Advertising expenses'],"['Advertising expenses', 0.9654314517974854, 'What is approximately $2.0 billion ?', 'Advertising expenses']",Advertising expenses,0.9654314517974854,What is approximately $2.0 billion ?,Advertising expenses,"Advertising expenses in 2021

Entity:
approximately $1.8 billion
Phrase:
Advertising expenses in 2020

Entity:
approximately $2.3 billion
Phrase:
Advertising expenses in 2019"
26,"Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.",1.8,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,pfe,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",$1.8 billion,MONEY,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",['Advertising expenses'],"['Advertising expenses', 0.4790500998497009, 'What is $1.8 billion ?', 'Advertising expenses']",Advertising expenses,0.4790500998497009,What is $1.8 billion ?,Advertising expenses,Advertising expenses in 2020
27,"Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.",2.3,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,pfe,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",$2.3 billion,MONEY,"Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019.",['Advertising expenses'],"['Advertising expenses', 0.6315742135047913, 'What is $2.3 billion ?', 'Advertising expenses']",Advertising expenses,0.6315742135047913,What is $2.3 billion ?,Advertising expenses,Advertising expenses in 2019
28,"On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash acquired. As a result, Trillium became our wholly owned subsidiary. We previously held a 2% ownership investment in Trillium. Trillium's lead program, TTI 622, is an investigational fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.",2.0,"['Asset acquisition, consideration transferred']",us-gaap_AssetAcquisitionConsiderationTransferred,monetaryItemType,pfe,"On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash acquired.",$2.0 billion,MONEY,"On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash acquired.","['price', 'price in cash', 'total consideration', 'net of cash', 'issued common stock', 'immune evasion pathways', 'total consideration']","['net of cash', 0.9779309034347534, 'what is net of cash ?', '$2.0 billion']",net of cash,0.9779309034347534,what is net of cash ?,$2.0 billion,All of the issued and outstanding common stock
29,"We accounted for the transaction as an asset acquisition since the lead asset, TTI 622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.",2.1,['Charge to research and development expenses in connection with asset acquisition'],us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff,monetaryItemType,pfe,"At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities.",$2.1 billion,MONEY,"At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities.","['alternative future use in expenses', 'acquisition date', 'IPR&D asset', 'alternative future use', 'net cash consideration', 'cash outflow', 'operating activities']","['acquisition date', 0.20078377425670624, 'what is acquisition date ?', '$2.1 billion']",acquisition date,0.2007837742567062,what is acquisition date ?,$2.1 billion,Acquired IPR&D asset
30,"We accounted for the transaction as an asset acquisition since the lead asset, TTI 622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.",2.0,"['Asset acquisition, consideration transferred']",us-gaap_AssetAcquisitionConsiderationTransferred,monetaryItemType,pfe,"At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities.",$2.0 billion,MONEY,"At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities.","['alternative future use in expenses', 'acquisition date', 'IPR&D asset', 'alternative future use', 'net cash consideration', 'cash outflow', 'operating activities']","['cash outflow', 0.3968704342842102, 'what is cash outflow ?', '$2.0 billion']",cash outflow,0.3968704342842102,what is cash outflow ?,$2.0 billion,net cash consideration
31,"We accounted for the transaction as an asset acquisition since the lead asset, TTI 622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.",256,"['Asset acquisition, assets acquired']",pfe_AssetAcquisitionAssetsAcquired,monetaryItemType,pfe,"In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments.",$256 million,MONEY,"In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments.",['connection with acquisition'],"['assets acquired primarily consisting of cash and investments', 0.5319244861602783, 'What is $256 million ?', 'assets acquired primarily consisting of cash and investments']",assets acquired primarily consisting of cash and investments,0.5319244861602783,What is $256 million ?,assets acquired primarily consisting of cash and investments,Assets acquired
32,"We accounted for the transaction as an asset acquisition since the lead asset, TTI 622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.",81,"['Asset acquisition, liabilities assumed']",pfe_AssetAcquisitionLiabilitiesAssumed,monetaryItemType,pfe,Liabilities assumed were approximately $81 million.,approximately $81 million,MONEY,Liabilities assumed were approximately $81 million.,[],"['Liabilities', 0.972490668296814, 'What is approximately $81 million ?', 'Liabilities']",Liabilities,0.972490668296814,What is approximately $81 million ?,Liabilities,Liabilities assumed
33,"On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post closing compensation expense and recorded in Restructuring charges and certain acquisition related costs (see Note 3). We financed the majority of the transaction with debt and the balance with existing cash.",11.2,"['Payments to acquire businesses, cash portion']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,pfe,"The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired).",$11.2 billion,MONEY,"The total fair value of the consideration transferred was $11.2 billion $10.9 billion, net of cash acquired.","['total fair value of consideration', 'net of cash', 'total fair value']","['total fair value of consideration', 0.579245924949646, 'what is total fair value of consideration ?', '$11.2 billion $10.9 billion']",total fair value of consideration,0.579245924949646,what is total fair value of consideration ?,$11.2 billion $10.9 billion,"The total fair value of the consideration transferred

Entity: 
$10.9 billion
Phrase: 
net of cash acquired"
34,"On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post closing compensation expense and recorded in Restructuring charges and certain acquisition related costs (see Note 3). We financed the majority of the transaction with debt and the balance with existing cash.",10.9,"['Cash payments for acquisition, net of cash acquired']",us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired,monetaryItemType,pfe,"The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired).",$10.9 billion,MONEY,"The total fair value of the consideration transferred was $11.2 billion $10.9 billion, net of cash acquired.","['total fair value of consideration', 'net of cash', 'total fair value']","['net of cash', 0.7539568543434143, 'what is net of cash ?', '$10.9 billion']",net of cash,0.7539568543434143,what is net of cash ?,$10.9 billion,Cash acquired
35,"On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post closing compensation expense and recorded in Restructuring charges and certain acquisition related costs (see Note 3). We financed the majority of the transaction with debt and the balance with existing cash.",157,['Post closing compensation expense'],us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized,monetaryItemType,pfe,"In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post closing compensation expense and recorded in Restructuring charges and certain acquisition related costs (see Note 3).",$157 million,MONEY,"In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post closing compensation expense and recorded in Restructuring charges and certain acquisition related costs see Note 3.","['payments to Array employees', 'Array employees for fair value', 'fair value of unvested stock options', 'Array employees', 'fair value', 'unvested stock options', 'compensation expense', 'Restructuring charges']","['payments to Array employees', 0.18642877042293549, 'What is $157 million ?', 'payments to Array employees']",payments to Array employees,0.1864287704229354,What is $157 million ?,payments to Array employees,Payments to Array employees
36,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",6.3,['Intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$6.3 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['Identifiable intangible assets', 0.7434073090553284, 'What is $6.3 billion ?', 'Identifiable intangible assets']",Identifiable intangible assets,0.7434073090553284,What is $6.3 billion ?,Identifiable intangible assets,Identifiable intangible assets
37,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",2.0,['Identifiable intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$2.0 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['Developed technology rights', 0.22169095277786255, 'What is $2.0 billion ?', 'Developed technology rights']",Developed technology rights,0.2216909527778625,What is $2.0 billion ?,Developed technology rights,Developed technology rights
38,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",16,"['Acquired intangible assets, useful life']",us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",16 years,DATE,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['Developed technology rights with useful life', 0.9326115250587463, 'what is Developed technology rights with useful life ?', '16 years']",Developed technology rights with useful life,0.9326115250587464,what is Developed technology rights with useful life ?,16 years,Useful life of developed technology rights
39,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",2.8,['Identifiable intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$2.8 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['IPR&D', 0.8834633827209473, 'What is $2.8 billion ?', 'IPR&D']",IPR&D,0.8834633827209473,What is $2.8 billion ?,IPR&D,IPR&D
40,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",1.5,['Intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$1.5 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['Licensing agreements', 0.8594642877578735, 'what is Licensing agreements ?', '$1.5 billion']",Licensing agreements,0.8594642877578735,what is Licensing agreements ?,$1.5 billion,Developed technology rights
41,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",1.2,['Intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$1.2 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['', 0, '', '']",,0.0,,,Technology in development
42,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",360,['Identifiable intangible assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$360 million,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['developed technology', 0.88634192943573, 'What is $360 million ?', 'developed technology']",developed technology,0.88634192943573,What is $360 million ?,developed technology,Developed technology finite lived licensing agreements
43,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",10,"['Finite lived intangible asset, useful life']",us-gaap_FiniteLivedIntangibleAssetUsefulLife,durationItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",10 years,DATE,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['finite lived licensing agreements', 0.5503538846969604, 'What is 10 years ?', 'finite lived licensing agreements']",finite lived licensing agreements,0.5503538846969604,What is 10 years ?,finite lived licensing agreements,Developed technology licensing agreements
44,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",6.1,['Goodwill'],us-gaap_Goodwill,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$6.1 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['Identifiable intangible assets', 0.3037845194339752, 'What is $6.1 billion ?', 'Identifiable intangible assets']",Identifiable intangible assets,0.3037845194339752,What is $6.1 billion ?,Identifiable intangible assets,Goodwill
45,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",1.1,['Net deferred tax liabilities'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$1.1 billion,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['net tax liabilities', 0.9788931608200073, 'what is net tax liabilities ?', '$1.1 billion']",net tax liabilities,0.9788931608200072,what is net tax liabilities ?,$1.1 billion,net deferred tax liabilities
46,"The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",451,['Assumed long term debt'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt,monetaryItemType,pfe,"In connection with this acquisition, we recorded: (i) $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other ($1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long term debt, which was paid in full in 2019.",$451 million,MONEY,"In connection with this acquisition, we recorded:  $6.3 billion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing agreements and other $1.2 billion for technology in development––indefinite lived licensing agreements and $360 million for developed technology––finite lived licensing agreements with a useful life of 10 years,  $6.1 billion of Goodwill,  $1.1 billion of net deferred tax liabilities and  $451 million of assumed long term debt, which was paid in full in 2019.","['connection with acquisition', 'Developed technology rights with useful life', 'useful life of years', 'useful life of years', 'Identifiable intangible assets', 'technology rights', 'useful life', 'Licensing agreements', 'licensing agreements', 'licensing agreements', 'useful life', 'net tax liabilities', 'assumed term debt']","['assumed term debt', 0.9579108953475952, 'what is assumed term debt ?', '$451 million']",assumed term debt,0.9579108953475952,what is assumed term debt ?,$451 million,Assumed long term debt
47,"In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in Identifiable intangible assets of approximately $900 million with a corresponding change to Goodwill and net deferred tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date and did not have a material impact on our consolidated statement of income for the year ended December 31, 2020.",900,[],us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles,monetaryItemType,pfe,"In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in Identifiable intangible assets of approximately $900 million with a corresponding change to Goodwill and net deferred tax liabilities.",approximately $900 million,MONEY,"In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in Identifiable intangible assets of approximately $900 million with a corresponding change to Goodwill and net deferred tax liabilities.","['period adjustments to estimated fair values', 'reduction in Identifiable intangible assets', 'Identifiable intangible assets', 'reduction with corresponding change', 'corresponding change to Goodwill', 'period adjustments', 'fair values', 'Identifiable intangible assets', 'corresponding change']","['reduction in Identifiable intangible assets', 0.5222078561782837, 'What is approximately $900 million ?', 'reduction in Identifiable intangible assets']",reduction in Identifiable intangible assets,0.5222078561782837,What is approximately $900 million ?,reduction in Identifiable intangible assets,Identifiable intangible assets
48,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $322 million, which consisted of $317 million of cash and our previous $5 million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $337 million in Research and development expenses.",340,['Upfront payment'],pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment,monetaryItemType,pfe,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset.",$340 million,MONEY,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset.","['remaining shares of Therachon', 'assets in development', 'assets for treatment', 'treatment of achondroplasia', 'common form of limb dwarfism', 'potential milestone payments of contingent', 'potential milestone payments on achievement', 'achievement of key milestones', 'key milestones in development', 'development of lead asset', 'rare diseases', 'limb dwarfism', 'key milestones', 'lead asset']","['short limb dwarfism', 0.12296424061059952, 'What is $340 million ?', 'short limb dwarfism']",short limb dwarfism,0.1229642406105995,What is $340 million ?,short limb dwarfism,All remaining shares of Therachon
49,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $322 million, which consisted of $317 million of cash and our previous $5 million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $337 million in Research and development expenses.",470,['Maximum potential milestone payments'],pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum,monetaryItemType,pfe,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset.",up to $470 million,MONEY,"On July 1, 2019, we acquired all the remaining shares of Therachon, a privately held clinical stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset.","['remaining shares of Therachon', 'assets in development', 'assets for treatment', 'treatment of achondroplasia', 'common form of limb dwarfism', 'potential milestone payments of contingent', 'potential milestone payments on achievement', 'achievement of key milestones', 'key milestones in development', 'development of lead asset', 'rare diseases', 'limb dwarfism', 'key milestones', 'lead asset']","['potential milestone payments on achievement', 0.7049434781074524, 'what is potential milestone payments on achievement ?', 'up to $470 million']",potential milestone payments on achievement,0.7049434781074524,what is potential milestone payments on achievement ?,up to $470 million,contingent on the achievement of key milestones
